Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 101 Solid sales growth driven by the US, International Operations and Region China Reported annual sales Diabetes Biopharmaceuticals Reported annual sales split by region Int. Operations DKK billion USA Europe Region China Pacific 120 CAGR¹ 12.9% 13% 5% 100 9% 8% 14% 13% 80 19% 29% 60 79% 78% 40 78% 76% 20 75% 53% 38% 0 2011 2012 2013 2014 2015 2011 2015 1 CAGR for 4-year period changing diabetes novo nordisk

View entire presentation